{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'sum, then only the short axis is added into the sum. The baseline sum diameters will be', 'used as reference to further characterize any objective tumor regression in the', 'measurable dimension of the disease.', 'Non-target lesions: All other lesions (or sites of disease) including any measurable', 'lesions over and above the 5 target lesions should be identified as non-target lesions', 'and should also be recorded at baseline. Measurements of these lesions are not', 'required, but the presence, absence, or in rare cases unequivocal progression of each', 'should be noted throughout follow-up.', 'Methods for Evaluation of Measurable Disease', 'All measurements should be taken and recorded in metric notation using a ruler or calipers. All', 'baseline evaluations should be performed as closely as possible to the beginning of treatment and', 'never more than 4 weeks before the beginning of the treatment.', 'The same method of assessment and the same technique should be used to characterize each', 'identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is', 'preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be', 'imaged but are assessable by clinical exam.', 'Clinical lesions. Clinical lesions will only be considered measurable when they are', 'superficial (eg, skin nodules and palpable lymph nodes) and >10 mm (1 cm) diameter', 'as assessed using calipers (eg, skin nodules). In the case of skin lesions, documentation', 'by color photography, including a ruler to estimate the size of the lesion, is', 'recommended.', 'Chest x-ray. Lesions on chest x-ray are acceptable as measurable lesions when they', 'are clearly defined and surrounded by aerated lung. However, CT is preferable.', 'Conventional CT and MRI. This guideline has defined measurability of lesions on', 'CT scan based on the assumption that CT slice thickness is 5 mm (0.5 cm) or less. If', 'CT scans have slice thickness greater than 5 mm (0.5 cm), the minimum size for a', 'measurable lesion should be twice the slice thickness. MRI is also acceptable in certain', 'situation.', 'PET-CT. At present, the low dose or attenuation correction CT portion of a combined', 'PET-CT is not always of optimal diagnostic CT quality for use with RECIST', 'measurements. However, if the site can document that the CT performed as part of a', 'PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast),', 'then the CT portion of the PET-CT can be used for RECIST measurements and can be', 'used interchangeably with conventional CT in accurately measuring cancer lesions', 'over time. Note, however, that the PET portion of the CT introduces additional data,', 'which may bias an investigator if it is not routinely or serially performed.', 'Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be', 'used as a method of measurement. Ultrasound examinations cannot be reproduced in', 'their entirety for independent review at a later date and, because they are operator', 'dependent, it cannot be guaranteed that the same technique and measurements will be', 'taken from one assessment to the next. If new lesions are identified by ultrasound in', 'Regeneron Pharmaceuticals, Inc.', 'Page 113 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'the course of the study, confirmation by CT or MRI is advised. If there is concern about', 'radiation exposure at CT, MRI may be used instead of CT in selected instances.', 'Endoscopy, Laparoscopy. The utilization of these techniques for objective tumor', 'evaluation is not advised. However, such techniques may be useful to confirm complete', 'pathological response when biopsies are obtained or to determine relapse in trials where', 'recurrence following CR or surgical resection is an endpoint.', 'Tumor markers. Tumor markers alone cannot be used to assess response. If markers', 'are initially above the upper normal limit, they must normalize for a patient to be', 'considered in complete clinical response.', 'Cytology, Histology. These techniques can be used to differentiate between partial', 'responses (PR) and CR in rare cases (eg, residual lesions in tumor types, such as germ', 'cell tumors, where known residual benign tumors can remain).', 'The cytological confirmation of the neoplastic origin of any effusion that appears or worsens', 'during treatment when the measurable tumor has met criteria for response or stable disease', 'is mandatory to differentiate between response or stable disease (an effusion may be a side', 'effect of the treatment) and progressive disease', 'IFF-fluorodeoxyglucose positron emission tomography (FDG-PET). While', 'FDG-PET response assessments need additional study, it is sometimes reasonable to', 'incorporate the use of FDG-PET scanning to complement CT scanning in assessment', \"of progression (particularly possible 'new' disease). New lesions on the basis of\", 'FDG-PET imaging can be identified according to the following algorithm:', 'a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD', 'based on a new lesion.', 'b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive', 'FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is', 'PD. If the positive FDG-PET at follow-up is not confirmed as a new site of disease on', 'CT, additional follow-up CT scans are needed to determine if there is truly progression', 'occurring at that site (if so, the date of PD will be the date of the initial abnormal', 'FDG-PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing', 'site of disease on CT that is not progressing on the basis of the anatomic images, this', 'is not PD.', 'c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy', 'in cases where a residual radiographic abnormality is thought to represent fibrosis or', 'scarring. The use of FDG-PET in this circumstance should be prospectively described', 'in the protocol and supported by disease-specific medical literature for the indication.', 'However, it must be acknowledged that both approaches may lead to false positive CR', 'due to limitations of FDG-PET and biopsy resolution/sensitivity.', 'NOTE: A \"positive\\' FDG-PET scan lesion means one that is FDG avid with an uptake', 'greater than twice that of the surrounding tissue on the attenuation corrected image.', 'Regeneron Pharmaceuticals, Inc.', 'Page 114 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}